The landmark findings of the ISCHEMIA trial favouring conservative therapy for stable coronary artery disease (CAD) are at risk of being overlooked because of the COVID-19 pandemic, according to a panel discussion at CSANZ 2020. The study results, first released in late 2019, showed no benefit of routine invasive therapy on major adverse cardiovascular events ...
Will ISCHEMIA study findings be translated into practice for patients with stable CAD?
By Michael Woodhead
15 Dec 2020